SLRX insider filings

Salarius Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-01-02. Screen SLRX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for SLRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Salarius Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2026-01-024HANISH ARNOLD C — DirectorSale (S): 15 @ $0.64 · Sale (S): 12 @ $0.64EDGAR
2025-11-244HANISH ARNOLD C — DirectorPurchase (P): 5,000 @ $0.75EDGAR
2025-11-204Rosenblum Mark J — Exec VP Finance, CFOPurchase (P): 20,000 @ $0.80EDGAR
2024-04-124Arthur David J. — Chief Executive Officer, DirectorGrant/award (A): 20,500 (derivative) @ $0EDGAR
2024-02-224McVicar William K. — DirectorGrant/award (A): 20,500 (derivative) @ $0EDGAR
2024-02-224McCreedy Bruce J Jr. — DirectorGrant/award (A): 20,500 (derivative) @ $0EDGAR
2024-02-224Burleson Tess — DirectorGrant/award (A): 20,500 (derivative) @ $0EDGAR
2024-02-224Lammers Paul — DirectorGrant/award (A): 20,500 (derivative) @ $0EDGAR
2024-02-224Lieber Jonathan I — DirectorGrant/award (A): 20,500 (derivative) @ $0EDGAR
2024-02-224Rosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 22,500 (derivative) @ $0EDGAR
2024-02-224HANISH ARNOLD C — DirectorGrant/award (A): 20,500 (derivative) @ $0EDGAR
2023-02-154Arthur David J. — Chief Executive Officer, DirectorGrant/award (A): 14,300 @ $0EDGAR
2023-02-154Rosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 6,432 @ $0EDGAR
2023-01-054McCreedy Bruce J Jr. — DirectorGrant/award (A): 1,440 @ $0EDGAR
2023-01-054Burleson Tess — DirectorGrant/award (A): 1,440 @ $0EDGAR
2023-01-054McVicar William K. — DirectorGrant/award (A): 1,440 @ $0EDGAR
2023-01-054Arthur David J. — Chief Executive Officer, DirectorGrant/award (A): 20,000 @ $0EDGAR
2023-01-054Lammers Paul — DirectorGrant/award (A): 1,440 @ $0EDGAR
2023-01-054Lieber Jonathan I — DirectorGrant/award (A): 1,440 @ $0EDGAR
2023-01-054Rosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 8,000 @ $0EDGAR
2023-01-054HANISH ARNOLD C — DirectorGrant/award (A): 1,440 @ $0EDGAR
2022-12-124/AArthur David J. — Chief Executive Officer, DirectorGrant/award (A): 2,693 @ $1.73EDGAR
2022-12-124/ARosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 1,488 @ $1.73EDGAR
2022-11-084/AArthur David J. — Chief Executive Officer, DirectorGrant/award (A): 10,000 @ $1.73EDGAR
2022-11-084/ARosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 7,314 @ $1.73EDGAR
2022-11-074Arthur David J. — Chief Executive Officer, DirectorGrant/award (A): 10,000 @ $1.73EDGAR
2022-11-074Rosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 7,314 @ $1.73EDGAR
2022-06-084Burleson Tess — DirectorPurchase (P): 27,700 @ $0.18EDGAR
2022-06-084Lieber Jonathan I — DirectorPurchase (P): 37,500 @ $0.19EDGAR
2022-06-074McVicar William K. — DirectorPurchase (P): 26,553 @ $0.19EDGAR
2022-06-064HANISH ARNOLD C — DirectorPurchase (P): 28,000 @ $0.18EDGAR
2022-06-064/AHANISH ARNOLD C — DirectorPurchase (P): 4,000 @ $0.98EDGAR
2022-06-064/AHANISH ARNOLD C — DirectorPurchase (P): 4,350 @ $1.15EDGAR
2022-06-064/AHANISH ARNOLD C — DirectorPurchase (P): 3,000 @ $3.59EDGAR
2022-05-314Arthur David J. — Chief Executive Officer, DirectorPurchase (P): 3,400 @ $0.18 · Purchase (P): 18,600 @ $0.18 · Purchase (P): 708 @ $0.18 · Purchase (P): 10,392 @ $0.18 · Purchase (P): 10,800 @ $0.18EDGAR
2022-05-314Rosenblum Mark J — Exec VP Finance, CFOPurchase (P): 28,000 @ $0.18EDGAR
2022-05-054Arthur David J. — Chief Executive Officer, DirectorGrant/award (A): 10,000 @ $0.19EDGAR
2022-05-054Rosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 10,000 @ $0.19EDGAR
2022-03-094Arthur David J. — Chief Executive Officer, DirectorPurchase (P): 139,488 @ $0.39EDGAR
2022-03-094Rosenblum Mark J — Exec VP Finance, CFOPurchase (P): 76,246 @ $0.39EDGAR
2022-01-214McCreedy Bruce J Jr. — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-01-214McVicar William K. — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-01-214Arthur David J. — Chief Executive Officer, DirectorGrant/award (A): 500,000 (derivative) @ $0EDGAR
2022-01-214Burleson Tess — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-01-214Lammers Paul — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-01-214Lieber Jonathan I — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-01-214Rosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 200,000 (derivative) @ $0EDGAR
2022-01-214HANISH ARNOLD C — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2021-11-054Arthur David J. — Chief Executive Officer, DirectorGrant/award (A): 7,939 @ $0.72EDGAR
2021-11-054Rosenblum Mark J — Exec VP Finance, CFOGrant/award (A): 7,787 @ $0.72EDGAR

Recent 8-K events — Salarius Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-09-238-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-158-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-07-158-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-06-298-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-198-K?
8.01 — Other Events
EDGAR
2026-04-028-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-058-K3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-258-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-01-088-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-028-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR

Registration filings — Salarius Pharmaceuticals, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=SLRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs